Search
Cerivastatin
go.drugbank.com/drugs/DB00439ApprovedWithdrawnIt has also been withdrawn from the Canadian market.[A669,L43942] … Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from
Categories: Hypolipidemic Agents Indicated for HyperlipidemiaPalbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigational[L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male … patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
Miglitol
go.drugbank.com/drugs/DB00491ApprovedUnlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys. … It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into
Sodium hydroxide
go.drugbank.com/drugs/DB11151ApprovedSodium hydroxide is also known as _lye_ or _soda_ , or _caustic soda_ [L1971]. At room temperature, sodium hydroxide is a white crystalline odorless solid that absorbs moisture from the air. … Interestingly, sodium hydroxide has been studied for its use in the treatment of prion disease (as occurs in mad cow disease and kuru).
Mixtures: OMEGA PLUS EMULSION FOR INFUSION, OMEGA SPECIAL EMULSION FOR INFUSIONCategories: Compounds used in a research, industrial, or household settingCyproheptadine
go.drugbank.com/drugs/DB00434ApprovedInvestigational[L32474] It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of serotonin syndrome.
Categories: Antihistamines for Systemic UseEquine Botulinum Neurotoxin G Immune FAB2
go.drugbank.com/drugs/DB13899ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients. … Equine Botulinum Neurotoxin G Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype G.
Equine Botulinum Neurotoxin D Immune FAB2
go.drugbank.com/drugs/DB13902ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients. … Equine Botulinum Neurotoxin D Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype D.
Copper histidinate
go.drugbank.com/drugs/DB32041ApprovedIt was approved by the US FDA in January 2026 for the treatment of pediatric patients with Menkes disease.[L54993,L54998] … Menkes disease is a rare, X-linked recessive disorder caused by pathogenic variants in the ATP7A gene, which encodes a copper transport protein essential for absorbing dietary copper and transporting it
Cenobamate
go.drugbank.com/drugs/DB06119ApprovedInvestigationalCenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.
Tenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigational[T239] Tenofovir alafenamide is an alanine ester form characterized for presenting low systemic levels but high intracellular concentration. … [L4388,L9010] Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval on 5 November 2015.[L6271]
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use